Please login to the form below

Not currently logged in

Dr Paula Salmikangas joins NDA Group

Moves to the regulatory affairs consultancy from the Finnish Medicines Agency

Paula SalmikaUK-headquartered regulatory affairs consultancy the NDA Group has appointed Dr Paula Salmikangas as a director.

She is the former chair of the EMA’s Committee for Advanced Therapies and comes to NDA from the Finnish Medicines Agency, where she served as a research professor.

She has also served as an adjunct professor of biochemistry for the University of Helsinki since 2006.

Dr Werner Van den Eynde, VP of NDA’s Advisory Board, said: “I am very excited to welcome Dr Paula Salmikangas on board. With her experience in and in-depth knowledge of biopharmaceuticals and advanced therapies she will be able to add tremendous value to clients in these areas and help them to make new and promising medicines available to patients.”

Dr Salmikangas is the second recent senior appointment at NDA Group following the appointment of Dr Van den Eynde, who joined earlier this month as its new vice president.

25th September 2017

From: Regulatory



Featured jobs

Subscribe to our email news alerts


Add my company
Create Health

A healthcare marketing agency that shares your passion for making things better. Our clients with solve real health problems every...

Latest intelligence

The Biosimilar Challenge
How health behaviours and clinical outcomes are related
When HCPs understand patient activation levels they can actively guide patients towards more confident self-management of diverse health concerns....
The Periodic Table of Healthcare Communications
The definitive framework for building healthcare communication strategies and plans. Covering Brand Planning, Customer Experience and Multi-channel Marketing....